IVAX Diagnostics Exhibits at AACC
28 July 2011 - 7:57AM
Business Wire
IVAX Diagnostics, Inc. (NYSE Amex:IVD), a fully integrated in
vitro diagnostics company, announced that its three wholly-owned
subsidiaries – Diamedix Corporation, ImmunoVision, Inc. and Delta
Biologicals, S.r.l. – are participating as exhibitors in the 2011
American Association for Clinical Chemistry (AACC) Annual Meeting
and Clinical Lab Expo, which is currently ongoing in Atlanta,
Georgia.
Kevin Clark, President, Chief Executive Officer and Chief
Operating Officer of IVAX Diagnostics, said, “We are pleased to be
participating as an exhibitor at the AACC, which is the largest
clinical exposition in the world. We are showcasing our suite of
products, including our Mago® 4S automated ELISA and IFA
instrumentation system that received 510(k) clearance from the U.S.
Food and Drug Administration earlier this year, at booth #3805 at
the event. ERBA Diagnostics Mannheim GmbH, an in vitro diagnostics
company headquartered in Germany which owns, directly or
indirectly, approximately 77.8% of the issued and outstanding
shares of our common stock, is also participating as an exhibitor
at the AACC event and is showcasing its suite of products in booth
#3705.”
About IVAX Diagnostics, Inc.
IVAX Diagnostics, Inc. (www.ivaxdiagnostics.com), headquartered
in Miami, Florida, is a fully integrated in vitro diagnostics
company that develops, manufactures and distributes in the United
States and internationally, proprietary diagnostic reagents, test
kits and instrumentation, primarily for autoimmune and infectious
diseases, through its three subsidiaries: Diamedix Corporation
(U.S.), Delta Biologicals S.r.l. (Europe), and ImmunoVision, Inc.
(U.S.).
Safe Harbor Statement
Except for the historical matters contained herein, statements
in this press release are forward-looking and are made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Investors are cautioned that forward-looking
statements involve risks and uncertainties that may affect the
business and prospects of IVAX Diagnostics, Inc. Investors should
consider the economic, competitive, governmental, technological and
other risks and uncertainties discussed in IVAX Diagnostics’
filings with the Securities and Exchange Commission, including,
without limitation, the risks and uncertainties discussed under the
heading “Risk Factors” in such filings.
Ivax Diagnostics (AMEX:IVD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ivax Diagnostics (AMEX:IVD)
Historical Stock Chart
From Jul 2023 to Jul 2024